The civic record
Read. Follow. Verify.Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Last action · July 23, 2026: Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.Sponsors: Mike Quigley and 103 others
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Would Do
This bill extends federal funding and research programs for Amyotrophic Lateral Sclerosis (ALS) through 2031. It also introduces new requirements for clinical trial data sharing and mandates a comprehensive FDA report on progress in treating rare neurodegenerative diseases.
This legislation ensures the continuation of federal ALS research grants and regulatory programs through 2031, impacting the timeline for drug development and the availability of clinical trial data for patients and researchers.
Who It Would Affect
Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.
ALS patients and families
The bill dictates the timeline and regulatory framework for research into therapies for their condition.
Pharmaceutical manufacturers
Companies conducting ALS clinical trials must share interim data with the FDA to qualify for grant renewals.
Food and Drug Administration
The agency is tasked with new reporting requirements and oversight duties regarding clinical trial data.
Key Facts
- Extends the authorization of the Accelerating Access to Critical Therapies for ALS Act from 2026 to 2031.
- Requires the FDA to assess clinical trial enrollment data when reviewing grant renewal applications for investigational drugs.
- Mandates that manufacturers share interim clinical trial data with the FDA to facilitate grant renewal assessments.
- Expands the definition of 'phase 3' clinical trials to include combined phase 2/3 trials and planned trials not yet enrolling participants.
Show all 8 facts
- Requires the FDA Commissioner to publish an updated action plan for ALS and other rare neurodegenerative diseases within one year of enactment.
- Requires the FDA to report on the implementation and outcomes of the 2022 Action Plan for Rare Neurodegenerative Diseases.
- Mandates a GAO report on the program's progress to be submitted to Congress within four years of enactment.
- Expresses a Sense of Congress that funds should be directly appropriated to carry out the Act's provisions.
Frequently Asked Questions
How long will this program be extended?
What new information must drug manufacturers provide?
When will the public see a report on these efforts?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
Currently passed chamber. The next step in the legislative lifecycle is Law.
Procedural history
18 actions- Jul 23, 2026SenateReceived in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.
- Jul 22, 2026HouseMotion to reconsider laid on the table Agreed to without objection.
- Jul 22, 2026HouseFloorOn motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
- Jul 22, 2026HouseFloorPassed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
- Jul 22, 2026HouseConsidered as unfinished business. (consideration: CR H5159)
- Jul 20, 2026HouseAt the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
Show 12 earlier actions
- Jul 20, 2026HouseDEBATE - The House proceeded with forty minutes of debate on H.R. 8205.
- Jul 20, 2026HouseConsidered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653)
- Jul 20, 2026HouseMr. Guthrie moved to suspend the rules and pass the bill, as amended.
- Jul 9, 2026HousePlaced on the Union Calendar, Calendar No. 637.
- Jul 9, 2026HouseReported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.
- May 21, 2026HouseCommitteeOrdered to be Reported (Amended) by the Yeas and Nays: 46 - 0.
- May 21, 2026HouseCommittee Consideration and Mark-up Session Held
- May 13, 2026HouseForwarded by Subcommittee to Full Committee by Voice Vote.
- May 13, 2026HouseSubcommittee Consideration and Mark-up Session Held
- Apr 6, 2026HouseCommitteeReferred to the Subcommittee on Health.
- Apr 6, 2026HouseCommitteeReferred to the House Committee on Energy and Commerce.
- Apr 6, 2026HouseIntroducedIntroduced in House
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Sponsors
Show 99 more sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Increased Data Transparency
The bill shifts from simple funding authorization to requiring active sharing of interim clinical trial data between manufacturers and the FDA.
Connected Entities
Sources
www.congress.gov
Analysis Score
0–100- Significance75How much this matters to a regular citizen
- Controversy10Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz20Current news / social attention level
Publisher tools
